Cardiac Specific C-Reactive Protein Test Extended Across Multiple Platforms

The high sensitivity C-reactive protein (hsCRP) test is used for both risk assessment of future cardiovascular disease and risk stratification for the prognosis of recurrent cardiac events.

When used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes, hsCRP measurements are also useful as an independent marker of prognosis of recurrent events in patients with stable coronary disease or acute coronary syndrome.

Siemens Healthcare Diagnostics' (Orlando, FL, USA) hsCRP test was cleared by the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) as a predictor of risk for cardiovascular disease. Called the CardioPhase hsCRP test, it was originally cleared for use on the BN nephelometry systems.

The cardiac-specific hsCRP test is now available across multiple platforms including the BN nephelometry systems, Dimension and Dimension Vista integrated systems, the Stratus CS Acute Care Diagnostic System, Advia chemistry systems, and the Immulite immunoassay systems.

In the fast-growing cardiac testing market, Siemens offers a full line of tests that aid in the diagnosis of all stages of cardiovascular disease. The company's broad portfolio of cardiac tests can be run on multiple instrument platforms used in either the clinical laboratory or a point-of-care setting.

Siemens is a medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. As an integrated healthcare company, it combines imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services.

Related Links:
Siemens Healthcare Diagnostics
U.S. Food and Drug Administration